A PHASE 1, OPEN-LABEL, 2-ARM PARALLEL STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF PF-07054894 USING 2 14C-RADIOLABELED PF-07054894 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07054894 IN HEALTHY ADULT MALE PARTICIPANTS USING A 14C-MICROTRACER APPROACH
Latest Information Update: 07 Jul 2025
At a glance
- Drugs PF-07054894 (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 29 Jun 2025 Status changed from not yet recruiting to recruiting.
- 13 Jun 2025 New trial record